Skip to main content
Log in

Rituxan associated with PML, warns US FDA

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. FDA.Rituximab (marketed as Rituxan). Internet Document: [3 pages], Dec 2006. Available from: URL: http://www.fda.gov

  2. FDA.Life-threatening brain infection in patients with systemic lupus erythematosus after rituxan (Rituximab) treatment. Internet Document: [2 pages], 18 Dec 2006. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rituxan associated with PML, warns US FDA. React. Wkly. 1133, 3 (2007). https://doi.org/10.2165/00128415-200711330-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711330-00006

Keywords

Navigation